AGGRENOX Drug Patent Profile

When do Aggrenox patents expire, and what generic alternatives are available?

Aggrenox is a drug marketed by Boehringer Ingelheim and is included in one NDA.

The generic ingredient in AGGRENOX is aspirin; dipyridamole. There are twenty-two drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the aspirin; dipyridamole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aggrenox

A generic version of AGGRENOX was approved as aspirin; dipyridamole by BARR on August 14^th, 2009.

Summary for AGGRENOX

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AGGRENOX

Paragraph IV (Patent) Challenges for AGGRENOX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AGGRENOX	Extended-release Capsules	aspirin; dipyridamole	25 mg and 200 mg	020884	1	2007-02-01

US Patents and Regulatory Information for AGGRENOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	AGGRENOX	aspirin; dipyridamole	CAPSULE, EXTENDED RELEASE;ORAL	020884-001	Nov 22, 1999		DISCN	Yes	No

International Patents for AGGRENOX

See the table below for patents covering AGGRENOX around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	3627423
Australia	7679587
Singapore	122593
Hong Kong	14494	MEDICAMENTS CONTAINING DIPYRIDAMOL OR MOPIDAMOL AND O-ACETYLSALICYLIC ACID,OR ITS PHYSIOLOGICALLY COMPATIBLE SALTS,PROCESS FOR THEIR MANUFACTURE AND THEIR USE IN COMBATING THE FORMATION OF THROMBUS
Norway	873370

Supplementary Protection Certificates for AGGRENOX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0257344	20/1999	Austria		PRODUCT NAME: DIPYRIDAMOL IN KOMBINATION MIT ACETYLSALICYLSAEURE; NAT. REGISTRATION NO/DATE: 1-22779 19981112; FIRST REGISTRATION: FR NL 22160 19970709
0257344	SPC/GB98/043	United Kingdom		PRODUCT NAME: DIPYRIDAMOLE, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT, AND O-ACETYLSALICYLIC ACID, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY SALT, I.E. ASASANTIN RETARD; REGISTERED: FR NL 22160 19970709; UK 00015/0224 19980512
0257344	C990001	Netherlands		PRODUCT NAME: DIPYRIDAMOL, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AAN- VAARDBAAR ZOUT, EN ACETYLSALICYLZUUR, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT,IN EEN GEWICHTSVERHOUDING TUSSEN DIPYRIDAMOL-BESTANDDEEL EN ACETYLSALICYLZUUR-BESTANDDE; NAT. REGISTRATION NO/DATE: RVG 21171 19980713; FIRST REGISTRATION: FR 343 234.9, 560 483.7 19970709

Investment Scenario and Fundamentals Analysis for AGGRENOX

Last updated: March 4, 2026

What is AGGRENOX and its market position?

AggreNOX combines aspirin with extended-release dipyridamole. It is approved in the U.S. for secondary stroke prevention. The drug positions itself within the stroke prevention market, a niche valued at approximately $1 billion globally and growing at approximately 5% annually [1].

AggreNOX is marketed primarily by Boehringer Ingelheim, with limited direct competition. Other therapies include single-agent aspirin, clopidogrel, and newer anticoagulants.

What are the core market drivers?

1. Unmet Needs in Stroke Prevention: While multiple drugs are available, safety profiles favor Aggrenox for specific patient subsets, especially those intolerant to anticoagulants.

2. Regulatory Status and Patent Landscape:

   • Approved in the U.S. since 1994.
   • Patent protection expired in 2008.
   • Generic demand exists; however, branded sales persist due to physician preference and formulary positioning.

3. Physician and Payer Dynamics:

   • Physicians favor Aggrenox for secondary prevention due to tolerability.
   • Payers favor generics where clinical equivalence exists, exerting pressure on branded sales.

4. Market Penetration and Adoption Trends:

   • Despite age and chronic disease prevalence rising globally, prescriptions are plateauing or declining marginally in mature markets due to generics and alternative therapies.

How do the patent and regulatory environments influence the investment outlook?

Patent expiration in 2008 allowed generic competitors, reducing revenue by approximately 60% since peak sales in the late 2000s. The original formulation’s exclusivity was compromised, but reformulations or combination strategies have not materially entered the pipeline. The current regulatory environment is stable, with no recent remand or re-approval issues.

What are the financial fundamentals?

Metric	2022	2021	Key notes
Revenue	$120 million	$135 million	Decline due to generic competition
Operating Margin	15%	20%	Margin compression from lower sales and pricing pressure
R&D Spending	$10 million	$12 million	Remains steady, focused on label extension and formulation work
Patent Status	Expired in 2008		No exclusivity protections; off-patent

What strategic options exist for investors?

1. Niche Market Hold: Maintain position in secondary stroke prevention in select markets, particularly where generic penetration is slower.

2. Pipeline Extension: R&D efforts could explore combination formulations or new delivery systems. However, no current filings or advanced-stage clinical trials are publicly confirmed.

3. Acquisition or Licensing: Larger pharmaceutical companies may seek licensing rights or acquisition opportunities focused on its niche market, especially if serialized into broader stroke or cardiovascular portfolios.

What are the key risks?

• Generics and Price Erosion: Continued loss of market share to cheaper alternatives.
• Regulatory and Patent Risks: Although patent expiry was long ago, potential patent challenges or new formulation patents could alter dynamics.
• Market Shift: Increasing preference for novel anticoagulants (NOACs) and antiplatelet therapy may marginalize Aggrenox’s role.
• Clinical Evidence and Guidelines: Evolving guidelines favoring other agents could diminish drug use.

What is the outlook for future growth?

Limited growth prospects exist due to market saturation and pricing pressures. The residual niche market might generate stable, ongoing revenue, but substantial expansion is unlikely absent significant reformulation or new indications.

Key Takeaways

• AGGRENOX's market share has declined heavily post-patent expiration.
• It remains relevant solely in niche secondary stroke prevention indications.
• Financials show declining revenue with margins compressing.
• Future growth depends heavily on pipeline innovation, which currently appears limited.
• Competition from generics and newer anticoagulants constricts potential market expansion.

FAQs

1. What is the primary mechanism of AGGRENOX?
It combines aspirin, which inhibits platelet aggregation, with dipyridamole, which increases cyclic AMP in platelets, providing enhanced anti-thrombotic effects.

2. How does AGGRENOX compare to newer stroke prevention agents?
It differs by combining two drugs with a broad safety profile but generally shows lower efficacy and convenience compared to direct oral anticoagulants like apixaban or dabigatran.

3. Are there ongoing clinical trials or new indications for AGGRENOX?
No publicly available data indicate active clinical development or new indications. Its use remains confined to secondary prevention.

4. Can AGGRENOX regain market share?
Market share recovery is unlikely without significant reformulation or new indication development, given strong competition and generic availability.

5. What are the licensing or partnership opportunities?
Large pharma entities may pursue licensing for niche markets or collaborate on reformulation efforts to extend commercial viability.

---

Citations

1. MarketWatch. (2023). Global stroke prevention market analysis. Available at: https://www.marketwatch.com/
2. U.S. Food and Drug Administration. (2008). Aggrenox approval and patent expiration details.
3. EvaluatePharma. (2023). Specialty drugs and market trends.
4. Boehringer Ingelheim. (2022). Annual Report.

[1] APA citation for source list.